Derya SEYMAN, Nefise ÖZTOPRAK, Ayşegül SEREMET KESKİN, Kübra DEMİR ÖNDER, Hande BERK

Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients

Background/aim: As the experience has increased regarding SARS-CoV-2 in time, treatment trends have changed since the beginning of the pandemic. This study aimed to compare the outcomes of different treatment modalities for inpatients in a tertiary pandemic hospital in Antalya, Turkey. Materials and methods: Individuals aged 18 years and above who tested positive for SARS-CoV-2 in PCR with presenting COVIDrelated radiological findings, hospitalized for at least 3 days, and completed follow-up between March 15, 2020 and November 30, 2020 were included in the study. Patients’ data were reviewed retrospectively. Seven treatment groups based on the single or combined use of hydroxychloroquine, oseltamivir, favipiravir, and remdesivir were formed and compared in terms of mortality, survival, length of hospital stay, need for intensive care, and mechanical ventilation. Results: A total of 321 patients were included in the study. The length of hospital stay, the need for intensive care, and mechanical ventilation were lower in Group 1 (hydroxychloroquine) and Group 2 (hydroxychloroquine + oseltamivir) compared to the other groups (p < 0.05). No significant difference was determined in survival between treatment groups. Analysis of prognostic factors affecting overall survival revealed that the need for intensive care and mechanical ventilation increased mortality [11.1 times (p < 0.001) and 6.48 times (p < 0.001), respectively]. Conclusion: No significant difference was determined between different treatment protocols in terms of their impact on survival. To end the COVID-19 pandemic, there is an urgent need to develop highly efficient, rapid-acting, and orally available antiviral drugs.Key words: COVID-19, treatment, favipiravir, remdesivir, hydroxychloroquine

PDF

___

1. Batırel A. Specific treatment of COVID-19. Southern Clinics of Istanbul Eurasia 2020; 31: 31–41. doi: 10.14744/scie.2020.57704
2. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E et al. Compassionate use of remdesivir for patients with severe COVID-19. New England Journal of Medicine 2020; 382: 2327–2336. doi: 10.1056/nejmoa2007016
3. Pekcevik Y, Belet U. Patient management in the radiology department, the role of chest imaging during the SARSCoV-2 pandemic and chest CT findings related to COVID-19 pneumonia. Tepecik Eğitim ve Araştırma Dergisi 2020; 30: 195-212. doi: 10.5222/terh.2020.13549
4. Chen N, Zhou M, Dong X, Qu J, Gong F et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 395: 507–513. doi:10.1016/S0140-6736(20)30211-7
5. Wu J, Li W, Shi X, Chen Z, Jiang B et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). Journal of Internal Medicine 2020; 288: 128–138. doi:10.1111/ joim.13063
6. Tadic M, Cuspidi C, Grassi G, Mancia G. COVID-19 and arterial hypertension: hypothesis or evidence? Journal of Clinical Hypertension 2020; 2: 1120–1126. doi:10.1111/ jch.13925
7. Taylor EH, Hofmeyr R, Torborg A, van Tonder C, Boden R et al. Risk factors and interventions associated with mortality or survival in adult COVID-19 patients admitted to critical care: A systematic review and meta-analysis. Southern African Journal of Anaesthesia and Analgesia 2020; 26: 116–127. doi: 10.36303/SAJAA.2020.26.3.2428
8. Gao YD, Ding M, Dong X, Zhang JJ, Azkur AK et al. Risk factors for severe and critically ill COVID-19 patients: A review. Journal of Allergy and Clinical Immunology 2021; 76: 428–455. doi:10.1111/all.14657
9. Szente Fonseca SN, de Queiroz Sousa A, Wolkoff AG, Moreira MS, Pinto BC et al. Risk of hospitalization for COVID-19 outpatients treated with various drug regimens in Brazil: comparative analysis. Travel Medicine and Infectious Diseases 2020; 38. doi:10.1016/j.tmaid.2020.101906
10. Van Halem K, Bruyndonckx R, Van der Hilst J, Cox J, Driesen P et al. Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study. BMC Infectious Diseases 2020; 20: 897. doi: 10.1186/s12879-020-05605-3
11. Bhimraj A, Morgan RL, Hirsch Shumaker A, Lavergne V, Baden L et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19). Clinical Infectious Diseases 2020; 10: 1-13. doi:10.1093/cid/ciaa478
12. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Internal Medicine 2021; 181: 41–51. doi: 10.1001/ jamainternmed.2020.6252
13. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. New England Journal of Medicine 2020; 382: 2411–2418. doi:10.1056/NEJMoa2012410
14. Tang W, Cao Z, Han M, Wang Z, Chen J et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. British Medical Journal 2020; 369: m1849. doi:10.1136/ bmj.m1849
15. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. British Medical Journal 2020; 369: m1844. doi:10.1136/bmj.m1844
16. Chen Z, Hu J, Zhang Z, Jiang S, Han S et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv 2020; 7. doi:10.1101/2020.03.22.20040758
17. Repurposed antiviral drugs for COVID-19 interim WHO solidarity trial results. New England Journal of Medicine 2021; 384: 497–511. doi:10.1056/nejmoa2023184
18. Çiftçiler R, Haznedaroğlu İC, Tufan A, Öztürk MA. COVID-19 scientific publications from Turkey. Turkish Journal of Medical Sciences 2021; 51 (3). doi: 10.3906/sag-2010-261